Seroquel
(Quetiapine)ApprovedSmall molecule
Quetiapine is used to treat schizophrenia, bipolar disorder, and depression. It works by helping to balance certain chemicals in the brain that affect mood and thinking.[2] Seroquel is currently approved and in use across 49 indications[4].[1]
Seroquel is one of 873 small molecule programs targeting Metabolic Syndrome. It is currently in Approved.
49
Indications
254
Total Trials
11
Active Trials
872
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 47 indications
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Zocor
OOrganon and Co
Preclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Comtan
Orion Corporation, Orion PharmaPreclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Catapres
Boehringer IngelheimPreclinical
Vivarin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Schizophrenia25 trials
Show 22 more trials
Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia
Unknown status·—·N/A·NCT00231101·40 enrolled
Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
Completed·—·Phase 4·NCT00208143·20 enrolled
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
Completed·—·Phase 4·NCT00156715·23 enrolled
Bipolar Disorder16 trials
Show 13 more trials
Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT01195363·28 enrolled
Bipolar Depression11 trials
Show 8 more trials
TIA10 trials
Show 7 more trials
Bioequivalence Study of Quetiapine Fumarate Tablets 300 mg Under Fasting Condition
Completed·—·Phase 1·NCT01566487·54 enrolled
Major Depressive Disorder10 trials
Show 7 more trials
65 more indications
Psychosis8 trials
Antipsychotic to Treat Psychosis Syndrome
Unknown status·—·N/A·NCT02137616·300 enrolled
Show 5 more trials
Delirium8 trials
Show 5 more trials
Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium
Completed·—·Phase 3·NCT01811459·107 enrolled
Quetiapine as Prophylaxis for Delirium in CABG
Unknown status·—·N/A·NCT05801289·60 enrolled
Quetiapine in Prevention of Delirium
Completed·—·Phase 2·NCT05793632·90 enrolled
Efficacy and Safety7 trials
Show 4 more trials
Schizoaffective Disorder7 trials
Show 4 more trials
Generalized Anxiety Disorder5 trials
Insomnia4 trials
Fibromyalgia4 trials
Quetiapine Compared With Placebo in the Management of Fibromyalgia
Completed·—·Phase 4·NCT01458964·42 enrolled
Antipsychotics4 trials
Depression3 trials
Bipolar I Disorder3 trials
Monotherapy3 trials
Borderline personality disorder3 trials
Treatment3 trials
Obsessive-Compulsive Disorder3 trials
Cannabis Dependence2 trials
AIN2 trials
Tics2 trials
Brain Injury2 trials
Effectiveness2 trials
Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency
Completed·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 2·NCT00498628·224 enrolled
Social Anxiety Disorder2 trials
Quetiapine in Social Anxiety Disorder
Completed·—·Phase 2/3·NCT00215254·15 enrolled
Oral2 trials
Agitation2 trials
Postpartum Depression2 trials
Medication2 trials
Comparing Antipsychotic Medications in LBD Over Time
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT05590637·94 enrolled
Chronic Kidney Disease1 trial
Sleep Disorders in Chronic Kidney Disease Patients
Unknown status·—·Phase 1·NCT05240261·60 enrolled
Pneumonia1 trial
First-line Treatment1 trial
Efficacy1 trial
Adolescent1 trial
Treatment Resistant Depression1 trial
Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression
Unknown status·—·Phase 4·NCT04936126·150 enrolled
Anxiety1 trial
Partial Response1 trial
Post-Traumatic Stress Disorder1 trial
Adult1 trial
Safety and Efficacy1 trial
Sedation1 trial
Major Depression1 trial
Weight Change1 trial
Cocaine Dependence1 trial
Substance Use Disorders1 trial
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
Completed·—·Phase 4·NCT02845453·24 enrolled
Dementia1 trial
Psychiatric Disorder1 trial
Bipolar II Disorder1 trial
Aggressive Behavior1 trial
Drug Abuse1 trial
Functional Bowel Disorder1 trial
Anxiety Disorder1 trial
Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms
Completed·—·Phase 4·NCT00912535·39 enrolled
Obstructive Sleep Apnea1 trial
Regulatory
FDA Approval Timeline[5]
Sep 26, 1997
SEROQUEL
NDA NDA020639
May 17, 2007
SEROQUEL XR
NDA NDA022047
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Seroquel drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Quetiapine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details